Articles found by an AI-assisted PubMed search that may be missing from CancerImmunoDB, shared so that curators and users can see what is being considered.
Why this exists: the database holds only about 10 articles a year for 2021–2024, and a plain PubMed search cannot judge whether a paper fits the scope.
| Year | Screened | Likely relevant |
|---|---|---|
| 2026 | 99 | 61 |
| 2025 | 100 | 81 |
| 2024 | 98 | 72 |
| 2023 | 92 | 45 |
| 2022 | 100 | 52 |
| 2021 | 85 | 49 |
360 articles shown. “In the database” counts the entries the database already has for each drug the AI named (cell line / animal / patient).
| PMID | Year | Article | Drugs | Study type | Cancer type | In the database | Curator status |
|---|---|---|---|---|---|---|---|
| 40914375 | 2025 | NK cells limit the synergistic anti-tumor effect of PD-1 inhibition and βγ-biased IL-2. International journal of biological macromolecules Likely relevant The study investigates a biased IL-2 variant combined with PD-1 inhibitors in a colon cancer mouse model, analyzing NK cells and CD8+ T cell activation, infiltration, and exhaustion. | wild-type IL-2; Non-a-IL-2; PD-1 inhibitors | Animal | colon cancer | wild-type IL-2 0/0/0; Non-a-IL-2 0/0/0; PD-1 inhibitors 0/0/0 | Awaiting curator check |
| 40959092 | 2025 | Urokinase-type plasminogen activator deficiency enhances CD8+ T cell infiltration and anti-PD-1 therapy efficacy in prostate cancer. Frontiers in immunology Likely relevant The study tests the uPA inhibitor UK122 and anti-PD-1 therapy in mouse models and cell assays, evaluating CD8+ T cell infiltration, cytotoxicity, and PD-1 expression. | UK122; anti-PD-1; anti-CD19 CAR | Mixed | prostate cancer | UK122 0/0/0; anti-PD-1 14/36/0; anti-CD19 CAR 0/0/0 | Awaiting curator check |
| 40963914 | 2025 | Tumor-responsive cuproptosis nanoinducer realizing efficient PANoptosis for enhanced cancer immunotherapy. Theranostics Likely relevant The study tests nanoparticles inducing cuproptosis combined with immune checkpoint blockade in animal models and measures immune cell infiltration and immunogenic cell death. | Elesclomol-Cu@PDPA nanoparticles; immune checkpoint blockade | Animal | cancer (unspecified in abstract) | Elesclomol-Cu@PDPA nanoparticles 0/0/0; immune checkpoint blockade 0/1/0 | Awaiting curator check |
| 40983344 | 2025 | Autophagy inhibition improves the efficacy of anlotinib and PD-1 inhibitors in the treatment of NSCLC. Journal for immunotherapy of cancer Likely relevant The study experimentally tests anlotinib, anti-PD-1, and chloroquine in animal and in vitro models, and reports their effects on immune cell infiltration (CD8+ T cells, M2 macrophages) and the tumor microenvironment. | anlotinib; anti-PD-1; chloroquine | Animal | non-small cell lung cancer | anlotinib 0/0/0; anti-PD-1 14/36/0; chloroquine 3/0/1 | Awaiting curator check |
| 41005293 | 2025 | Intra-tumoral hypoxia promotes CD8+ T cell dysfunction via chronic activation of integrated stress response transcription factor ATF4. Immunity Likely relevant The study investigates genetic/pharmacologic attenuation of ATF4 combined with a PD-1 inhibitor in tumor models and measures CD8+ TIL viability and oxidative stress. | programmed cell death protein-1 (PD-1) inhibitor | Animal | various tumor models | programmed cell death protein-1 (PD-1) inhibitor 0/0/0 | Awaiting curator check |
| 41005300 | 2025 | Phocaeicola vulgatus induces immunotherapy resistance in hepatocellular carcinoma via reducing indoleacetic acid production. Cell reports. Medicine Likely relevant Investigates the effect of microbial metabolites and anti-PD-1 therapy on CD8+ T cell cytotoxicity and tumor models. | anti-PD-1; indoleacetic acid | Animal | hepatocellular carcinoma | anti-PD-1 14/36/0; indoleacetic acid 0/0/0 | Awaiting curator check |
| 41075789 | 2025 | Local delivery of IL-15 and anti-PD-L1 nanobody by in vitro-transcribed circILNb elicits superior antitumor immunity in cold tumors. Cell reports. Medicine Likely relevant The study tests lipid nanoparticle-encapsulated circILNb delivering IL-15 and anti-PD-L1, measuring CD8+ T cell activation and systemic immune responses. | circILNb (co-encoding IL-15 and anti-PD-L1 nanobody) | Mixed | tumors | circILNb (co-encoding IL-15 and anti-PD-L1 nanobody) 0/0/0 | Awaiting curator check |
| 41125717 | 2025 | Genistein enhances anti-PD-1 efficacy in melanoma by suppressing regulatory T cell differentiation and activity. Scientific reports Likely relevant The study tests genistein alone or with anti-PD-1 therapy in vitro and in a mouse melanoma model, measuring Treg differentiation, CD8+/Treg ratio, and immune infiltration. | genistein; anti-PD-1 | Mixed | melanoma | genistein 0/0/0; anti-PD-1 14/36/0 | Awaiting curator check |
| 41161002 | 2025 | Co-treatment of ticagrelor and anti-PD-1 immunotherapy in tumor-associated macrophages reduces pancreatic cancer cell growth and migration through the TGF-β1/Smad2 pathway. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie Likely relevant The study tests the combination of PD-1/PD-L1 blockers and ticagrelor on co-cultures of pancreatic cancer cells and TAMs, measuring effects on TAM phagocytosis and TGF-beta1 release. | BMS-1; cemiplimab; ticagrelor | Cell line | pancreatic ductal adenocarcinoma | BMS-1 0/0/0; cemiplimab 0/0/0; ticagrelor 0/0/0 | Awaiting curator check |
| 41197618 | 2025 | Trilaciclib triggers a neutrophil-related immune response and sensitizes non-small cell lung cancer to anti-PD-1 therapy. Cell reports. Medicine Likely relevant The study investigates trilaciclib combined with anti-PD-1 antibodies in NSCLC models and reports neutrophil and CD8+ T cell infiltration and activation. | trilaciclib; anti-PD-1 antibodies | Animal | non-small cell lung cancer | trilaciclib 0/0/0; anti-PD-1 antibodies 0/0/0 | Awaiting curator check |
| 41205593 | 2025 | Developing a therapeutic elastase that stimulates anti-tumor immunity by selectively killing cancer cells. Cell reports. Medicine Likely relevant The study tests a therapeutic elastase (N17350) across cancer cell lines, tumor models, and patient samples, and measures immunogenic cell death and CD8+ T cell activation. | N17350 | Mixed | cancer | N17350 0/0/0 | Awaiting curator check |
| 41246302 | 2025 | Immune suppression in MTAP-deficient cancers via glutamate metabolism and CXCL10 downregulation. Frontiers in immunology Likely relevant Tests the glutaminase inhibitor CB-839 in murine tumor models and evaluates its effect on immune signaling and CXCL10 expression. | CB-839 | Animal | MTAP-deficient cancers | CB-839 0/0/0 | Awaiting curator check |
| 41271647 | 2025 | Cancer cell-derived IL-1β reverses chemo-immunotherapy resistance in non-small cell lung cancer. Nature communications Likely relevant The study tests chemo-immunotherapy (cisplatin/pemetrexed/anti-PD-1) and targeted inhibitors in mouse models and patient tumors, measuring CD8 T cell recruitment. | cisplatin; pemetrexed; anti-PD-1; MEK inhibitors; MDM2 inhibitors | Mixed | non-small cell lung cancer | cisplatin 18/3/11; pemetrexed 3/3/0; anti-PD-1 14/36/0; MEK inhibitors 9/0/0 | Awaiting curator check |
| 41315371 | 2025 | Cellular reprogramming during anti-PD-1 and chemotherapy treatment in early-stage primary hormone receptor-positive breast cancer. Nature communications Likely relevant The study tests nab-paclitaxel and pembrolizumab in patients with breast cancer and measures immune cell states and pathways in biopsies. | nab-paclitaxel; pembrolizumab | Patient | breast cancer | nab-paclitaxel 0/0/0; pembrolizumab 0/0/16 | Awaiting curator check |
| 41328155 | 2025 | Co-Delivery of Chemotherapy and Anti-Angiogenic Lipid via DPPA-LNPs Potentiates Anti-PD-1 Immunotherapy. International journal of nanomedicine Likely relevant The study tests a chemotherapeutic nanoplatform combined with a PD-1 inhibitor in orthotopic mouse models and measures immunogenic cell death and TME immune activation. | epirubicin; DPPA(EPI) LNPs; programmed cell death protein 1 (PD-1) inhibitor | Animal | breast cancer and hepatocellular carcinoma | epirubicin 0/0/0; DPPA(EPI) LNPs 0/0/0; programmed cell death protein 1 (PD-1) inhibitor 0/0/0 | Awaiting curator check |
| 41406067 | 2025 | Combining Radiation and anti-PD-L1 Enhances the Antitumor Activity in Colorectal Cancer via IFN-γ-Dependent Activation of STAT1. Technology in cancer research & treatment Likely relevant The study tests ionizing radiation combined with anti-PD-L1 and the JAK1 inhibitor Itacitinib in a mouse colorectal cancer model and measures CD8+ T-cell infiltration and IFN-gamma levels. | anti-PD-L1; Itacitinib | Animal | colorectal cancer | anti-PD-L1 0/15/0; Itacitinib 0/0/0 | Awaiting curator check |
| 41613119 | 2025 | Enhancing anti-tumor immunity through co-blocking PD-L1 and TIGIT by facilitating tumor-directed responses and additional VEGF inhibition. Frontiers in immunology Likely relevant The study tests bispecific and combination antibodies targeting PD-L1, TIGIT, and VEGF in vitro and in tumor models, measuring T-cell proliferation and surface marker modulation. | HB0036 bispecific antibody; PD-L1 antibody; TIGIT antibody; VEGF blocker | Mixed | unspecified tumor models | HB0036 bispecific antibody 0/0/0; PD-L1 antibody 0/1/0; TIGIT antibody 0/0/0; VEGF blocker 0/0/0 | Awaiting curator check |
| 37749237 | 2024 | Rosmarinic acid in combination with ginsenoside Rg1 suppresses colon cancer metastasis via co-inhition of COX-2 and PD1/PD-L1 signaling axis. Acta pharmacologica Sinica Likely relevant The study tests rosmarinic acid and ginsenoside Rg1 in a mouse xenograft model of colorectal cancer, assessing PD-1/PD-L1 involvement. | rosmarinic acid; ginsenoside Rg1; Celecoxib | Animal | colon cancer | rosmarinic acid 0/0/0; ginsenoside Rg1 0/0/0; Celecoxib 6/4/0 | Awaiting curator check |
| 38057662 | 2024 | An IL-4 signalling axis in bone marrow drives pro-tumorigenic myelopoiesis. Nature Likely relevant The study experimentally tests dupilumab combined with checkpoint blockade in NSCLC patients and animal models, measuring circulating monocytes and CD8 T cell infiltration. | dupilumab; PD-1/PD-L1 checkpoint blockade | Mixed | non-small cell lung cancer | dupilumab 0/0/0; PD-1/PD-L1 checkpoint blockade 0/0/0 | Awaiting curator check |
| 38062129 | 2024 | The BCL-2 inhibitor APG-2575 resets tumor-associated macrophages toward the M1 phenotype, promoting a favorable response to anti-PD-1 therapy via NLRP3 activation. Cellular & molecular immunology Likely relevant Tests the BCL-2 inhibitor APG-2575 alone and combined with anti-PD-1 in mouse models, measuring macrophage repolarization, chemokine secretion, and T-cell function. | APG-2575; anti-PD-1 therapy | Animal | unspecified cancer (syngeneic and humanized CD34+ mouse models) | APG-2575 0/0/0; anti-PD-1 therapy 0/0/0 | Awaiting curator check |
| 38101956 | 2024 | Beyond probiotics: postbiotics sensitize cancer cells to immune checkpoint inhibitors. Trends in cancer Likely relevant The study tests postbiotics (phytosphingosine) and immune checkpoint inhibitors, reporting effects on T cell effector responses and NF-kB/NLRC5 activation. | phytosphingosine; immune checkpoint inhibitors | Mixed | cancer | phytosphingosine 0/0/0; immune checkpoint inhibitors 0/0/0 | Awaiting curator check |
| 38142035 | 2024 | Targeting acid ceramidase enhances antitumor immune response in colorectal cancer. Journal of advanced research Likely relevant The study tests an ASAH1 inhibitor (LCL-521) and anti-PD-1 antibody in human/mouse CRC cell lines and mouse models, measuring ICD, macrophage activation, and T cell infiltration. | LCL-521; anti-PD-1 antibody | Mixed | colorectal cancer (CRC) | LCL-521 0/0/0; anti-PD-1 antibody 0/2/0 | Awaiting curator check |
| 38207022 | 2024 | Hyperglycosylation of prosaposin in tumor dendritic cells drives immune escape. Science (New York, N.Y.) Likely relevant The study experimentally tests recombinant pSAP treatment on dendritic cells and tumor models, measuring its effect on T cell activation and tumor immunity. | recombinant pSAP | Mixed | melanoma | recombinant pSAP 0/0/0 | Awaiting curator check |
| 38417530 | 2024 | TGF-β1-Induced SOX18 Elevation Promotes Hepatocellular Carcinoma Progression and Metastasis Through Transcriptionally Upregulating PD-L1 and CXCL12. Gastroenterology Likely relevant The study tests Vactosertib or AMD3100 in combination with anti-PD-L1 in murine models and evaluates immune cell infiltration via flow cytometry and immunofluorescence. | Vactosertib; AMD3100; anti-PD-L1 | Animal | hepatocellular carcinoma | Vactosertib 0/0/0; AMD3100 1/7/0; anti-PD-L1 0/15/0 | Awaiting curator check |
| 38418879 | 2024 | Anti-TIGIT antibody improves PD-L1 blockade through myeloid and Treg cells. Nature Likely relevant Examines patient samples and mouse tumor models treated with anti-TIGIT and anti-PD-L1 antibodies, measuring macrophage activation and T cell state remodeling. | tiragolumab; atezolizumab | Mixed | cancer | tiragolumab 0/0/0; atezolizumab 0/0/4 | Awaiting curator check |